Treating resistant Pseudomonas aeruginosa lung disease in young children with cystic fibrosis

Sandy Z P Lim; Dominic A Fitzgerald

doi:10.1016/j.prrv.2017.08.001

Treating resistant Pseudomonas aeruginosa lung disease in young children with cystic fibrosis

Paediatr Respir Rev. 2018 Jun:27:33-36. doi: 10.1016/j.prrv.2017.08.001. Epub 2017 Sep 1.

Authors

Sandy Z P Lim¹, Dominic A Fitzgerald²

Affiliations

¹ Sydney Medical School, University of Sydney, Australia.
² The Children's Hospital at Westmead, Sydney, Australia; Sydney Medical School, Discipline Paediatrics & Child Health, University of Sydney, Australia. Electronic address: [email protected].

PMID: 29033215
DOI: 10.1016/j.prrv.2017.08.001

Abstract

Pseudomonas aeruginosa is a common bacterial pathogen in the evolution of bronchiectasis in cystic fibrosis. The appearance of resistant strains of pseudomonas is increasing with the earlier and more liberal use of a range of anti-pseudomonal antibiotics for the treatment of bacterial chest infections. The rationale for treatment and potential benefits of aggressive treatment of resistant strains of Pseudomonas aeruginosa from early in life are discussed.

Keywords: Cystic fibrosis; Lung disease; Resistant Pseudomonas aeruginosa; Treatment.

Publication types

Review

MeSH terms

Anti-Bacterial Agents / pharmacology
Child
Cystic Fibrosis* / complications
Cystic Fibrosis* / diagnosis
Cystic Fibrosis* / microbiology
Drug Resistance, Bacterial
Humans
Prognosis
Pseudomonas Infections / drug therapy*
Pseudomonas Infections / etiology
Pseudomonas aeruginosa* / drug effects
Pseudomonas aeruginosa* / isolation & purification
Pseudomonas aeruginosa* / pathogenicity
Treatment Outcome

Substances

Anti-Bacterial Agents